Dishman Pharma rallies after receiving EIR for Bavla facility
Shares of Dishman Pharmaceuticals and Chemicals gained as much as 4.56 per cent in early trade on Thursday after the company announced that it had received the Establishment Inspection Report (EIR) from the USFDA for its Bavla facility on Wednesday.
The scrip was trading 2.96 per cent higher at Rs 234.70 at around 10.50 am (IST). Shares of the pharma company opened at Rs 236.70 and touched a high and low of Rs 238.35 and Rs 233.15, respectively, in trade so far. The benchmark BSE Sensex was trading 37.45 points, or 0.13 per cent up at 28,179.09.
In a BSE filing, the company said, “The Bavla facility was successfully inspected by the US FDA in July, 2016, which was intimated to the stock exchanges on July 09, 2016. In this regard, the Company has received the Establishment Inspection Report (EIR) from the US FDA for this facility on February 01, 2017. Thus, the company's facilities in Bavla, Naroda and Switzerland continue to be approved by the US FDA.”
On the BSE, 1 lakh shares were traded on the counter so far against an average daily volume of 1.49 lakh shares in the past two weeks.
The scrip was trading 2.96 per cent higher at Rs 234.70 at around 10.50 am (IST). Shares of the pharma company opened at Rs 236.70 and touched a high and low of Rs 238.35 and Rs 233.15, respectively, in trade so far. The benchmark BSE Sensex was trading 37.45 points, or 0.13 per cent up at 28,179.09.
In a BSE filing, the company said, “The Bavla facility was successfully inspected by the US FDA in July, 2016, which was intimated to the stock exchanges on July 09, 2016. In this regard, the Company has received the Establishment Inspection Report (EIR) from the US FDA for this facility on February 01, 2017. Thus, the company's facilities in Bavla, Naroda and Switzerland continue to be approved by the US FDA.”
On the BSE, 1 lakh shares were traded on the counter so far against an average daily volume of 1.49 lakh shares in the past two weeks.
